english.prescrire.org > Spotlight > Archives : 2025 > Antineoplastic drugs that do not represent a therapeutic advance: still highly profitable

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2025 : 1 | 30

Antineoplastic drugs that do not represent a therapeutic advance: still highly profitable

 Outlook  Antineoplastic drugs that provide little or no progress for patients are nonetheless significant sources of revenue for pharmaceutical companies: between 1995 and 2020, these drugs generated half as much revenue as those that represented a major therapeutic advance.
Full article available for download (FREE)

 ©Prescrire 1 September 2025

Source: "Antineoplastic drugs that do not represent a therapeutic advance: still highly profitable" Prescrire Int 2025; 34 (273): 222-223. FREE.

Filet

Enjoy full access to Prescrire International, and support independent information

 

Share
Share on  Facebook  
 
 
See also:

"Pricing of new drugs:
deadlock"
Prescrire Int 2025;
34 (273): 199.
FREE

"Cancer drugs:
very profitable
for drug companies"
Prescrire Int 2020;
29 (211): 27.
FREE